Riesgo de hipercalcemia e hipervitaminosis D por calcifediol. Revisión de casos notificados al Sistema Español de Farmacovigilancia

García Doladé, Nuria; cereza García, Gloria; Madurga Sanz, Mariano; Montero Corominas, Dolores.
Med. clín (Ed. impr.) ; 141(2): 88-89, jul. 2013.
Artículo en Español | IBECS (España) | ID: ibc-114358

Documentos relacionados

  1. Hypercalcemia Associated with the Ectopic Expression of 25-hydroxyvitamin D3-1α-hydroxylase in Diffuse Large B-cell Lymphoma.
  2. Hypercalcemia, nephrolithiasis, and hypervitaminosis D precipitated by supplementation in a susceptible individual.
  3. Nephrocalcinosis in children who received high-dose vitamin D.
  4. Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial-POSCAL Study.
  5. Long-term supplementation with 3200 to 4000 IU of vitamin D daily and adverse events: a systematic review and meta-analysis of randomized controlled trials.
  6. Hypercalcemia, hypervitaminosis A and 3-epi-25-OH-D3 levels after consumption of an "over the counter" vitamin D remedy. a case report.
  7. Vitamin D supplementation: upper limit for safety revisited?
  8. Normocalcemic primary hyperparathyroidism is an early stage of primary hyperparathyroidism according to fibroblast growth factor 23 level.
  9. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D<sub>3</sub> combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal.
  10. Toxic Dose of Vitamin D-Induced Hypercalcemia.